

Global Burden of Disease

**Mental Disorders and
Illicit Drug Use Expert Group**



Fiona Charlson, Louisa Degenhardt, Jennifer McLaren, Wayne Hall and Michael Lynskey

Benzodiazepine-related mortality

Illicit Drugs Discussion Paper No. 1

BENZODIAZEPINE-RELATED MORTALITY

Fiona Charlson, Louisa Degenhardt, Jennifer McLaren, Wayne Hall and Michael Lynskey

Illicit Drugs Discussion Paper No. 1

Recommended citation:

Charlson, F., Degenhardt, L., McLaren, J., Hall, W., & Lynskey, M. (2008). *Benzodiazepine-related mortality. Global Burden of Disease Mental Disorders and Illicit Drug Use Expert group, Illicit drugs discussion paper No. 1*. National Drug and Alcohol Research Centre, University of NSW: Sydney.

ISBN: 978 0 7334 2688 9

**©NATIONAL DRUG AND ALCOHOL RESEARCH CENTRE,
UNIVERSITY OF NEW SOUTH WALES, SYDNEY, 2008**

This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia.

Table of contents

Summary and recommendations.....	1
1. Introduction.....	2
2. Methods.....	4
3. Results.....	5
3.1 Population-based registry studies.....	5
3.2 Cohort studies.....	7
4. Discussion.....	10
4.1 Limitations.....	10
4.2 Conclusions.....	12
5. References.....	13
Annex 1: Search strategy.....	18
Annex 2: Quality index.....	19

Summary and recommendations

- A thorough review of the literature on mortality associated with benzodiazepines was undertaken to determine:
 1. If there was sufficient evidence to conduct a comparative risk assessment for illicit benzodiazepine use;
 2. Examine the extent of elevation of mortality among heavy/dependent illicit benzodiazepine users.
- An extensive literature review was undertaken utilising Embase, PsycInfo and Medline databases to locate all English-language published articles that examine mortality risk associated with use of benzodiazepines from 1990 onwards.
- Six prospective cohort studies and three retrospective population-based registry studies meeting criteria were identified; all were from high-income countries within Europe and North America.
- The main findings from this small group of studies were:
 1. Increased mortality in regular users;
 2. An absence of data specific to illicit benzodiazepine use/dependence in the general population;
 3. No strong positive association with driver culpability in fatal road accidents;
 4. Increased mortality associated with benzodiazepine use among “drug misusers”; and
 5. Mixed and inconclusive results from cohort studies.
- On the basis of existing research it is considered that there is insufficient data to conduct a comparative risk assessment for specific causes of mortality related to benzodiazepine use. Future work should examine this issue.
- There is some evidence suggesting elevated mortality among older benzodiazepine users, but it is not clear whether such users are using in accordance with their prescription.
- For these reasons, it is considered that there is insufficient evidence to estimate the extent of mortality associated with benzodiazepine use that is independent from opioid-associated overdose, which will be attributed to opioids in the GBD exercise.

1. Introduction

Benzodiazepines have been widely used in clinical practice for over four decades and continue to be one of the most consumed and highly prescribed class of drugs available¹. Chlordiazepoxide (Librium) was first introduced to the market in 1960, and because of the relative safety of benzodiazepines, these agents rapidly replaced barbiturates as the preferred sedative-hypnotics².

Most hypnotic drugs are consumed by chronic users who often take a sleeping pill nightly for many years³. One study showed that in the U.S.A, 65% of total hypnotic consumption was by individuals who took 30 doses or more per month, and the median usage was reported as 5 years⁴. It has also been reported that the majority of hypnotics are used by persons over 60 years of age³. Among this population, prevalence rates of benzodiazepine usage greater than 20% have been reported^{3 5 6}. In a study examined in more detail in this review, a prevalence of 30% was found among the elderly population in The Netherlands⁷.

Benzodiazepines promote the binding of the major inhibitory neurotransmitter γ -Aminobutyric acid (GABA) to the GABAA subtype of GABA receptors in the central nervous system. Benzodiazepines are indicated for use in anxiety, insomnia, muscle spasticity including tetanus, acute behavioural disturbance, convulsive disorders, presurgical sedation, involuntary movement disorders, and detoxification from alcohol and other substances^{8 9}.

Benzodiazepines can be expected to cause varying degrees of drowsiness, light-headedness, lassitude, increased reaction time, dysarthria, ataxia, motor incoordination, impairment of mental and motor functions, confusion, depression and anterograde amnesia. When the drug is given at the intended time of sleep, the persistence of these effects during the waking hours is adverse. Studies of the psychomotor effects suggest that benzodiazepines slow reaction time and impair driving skills, increasing the risk of motor vehicle accidents in patients who are taking these agents^{2 10-16}. Among the elderly, a relationship between falls, hip fractures and benzodiazepine use has also been described, and is explained by the negative effect these drugs have on balance¹⁷⁻²². These dose-related residual effects can be insidious because most subjects underestimate the degree of their impairment²³⁻²⁵.

Benzodiazepines alone cause significantly less respiratory depression than barbiturates and even large doses are rarely fatal in acute situations. However, when other CNS-depressants, such as opioids, hypnotics, sedating antidepressants, neuroleptics, anticonvulsants, antihistamines and alcohol, are taken concomitantly, deaths involving benzodiazepines become more common place^{2 23 26 27}. The intensity and incidence of CNS toxicity generally increase with age; both pharmacokinetic and pharmacodynamic factors are involved¹⁹.

The specific concerns about the long-term use of benzodiazepines vary and include tolerance development and dose escalation, dependency, medication abuse and withdrawal difficulties, and an increased risk of death²⁵. Tolerance develops quickly to benzodiazepines, and can limit long term efficacy in some clinical conditions such as

seizures. Chronic benzodiazepine use poses a real risk for development of physiological and psychological dependence and abuse based on the drug's dosage, duration of therapy and potency^{2 25}. Both tolerance and dependence can lead to dose escalation and compounding of adverse events. Of significance is an association noted between benzodiazepine use and depressive symptoms and, in some cases, the intent or act of suicide²⁸⁻³⁰. Furthermore, other paradoxical reactions, such as behavioural disinhibition and aggression, can also occur with the use of benzodiazepines^{23 31}.

All of these adverse effects have created concern amongst the medical profession to some degree. Logic tells us that risks of impaired driving and falls in the elderly have the potential to create serious public health issues. But questions remain: are we underestimating the adverse effects of benzodiazepine use? Is there a link between benzodiazepine use and increased mortality? Historically, most of our knowledge about the long-term risks of hypnotic medications comes from voluntary reporting. Unfortunately, these sources are unreliable and we are left with examining clinical case series data to provide information on the long-term use of hypnotic medication.

The Global Burden of Disease, Injuries and Risk Factors Study (GBD Study 2005) is a follow-up from the original GBD Study of 1990^{32 33}. It involves a systematic assessment of the data on all diseases and injuries and will produce comprehensive and comparable estimates of the burden of diseases, injuries and risk factors across the globe. As part of this process, a systematic review was undertaken to determine the existing evidence of mortality risk for extra-medical illicit benzodiazepine use – that is, use *outside* the advice of a doctor or allied health professional. This was intended to inform decisions about the strength and quality of evidence for the conduct of estimates of the global burden of disease attributable to illicit benzodiazepine dependence¹.

Due to a dearth in literature and difficulties in distinguishing between illicit and non-illicit use of a widely used prescription medication, this systematic review was extended to include both prescription and non-prescription use, and both illicit and licit use. This paper aims to:

1. Examine whether there is evidence of elevated mortality risk among heavy or dependent benzodiazepine users;
2. Examine whether there is sufficient evidence of elevated risk of adverse outcomes of benzodiazepine use, such as deaths due to injuries, which might be examined as part of the “comparative risk assessment” component of the Global Burden of Disease project².


¹ Refer to GBD website <http://www.gbd.unsw.edu.au/>

² Comparative risk assessment allows the evaluation of the changes in population health which would result from modifying the population distribution of exposure to a risk factor or a group of risk factors

2. Methods

An extensive literature review was undertaken utilising Embase, PsycInfo and Medline databases to locate all English-language published articles that examine mortality risk associated with use of benzodiazepines from 1990 onwards (see Annex 1 for search terms used). Studies were graded (see Annex 2) to determine the quality of the research. A number of case-series studies present crude data from various sources that can provide useful sources for discussion³⁴⁻⁴⁸. However, it was decided crude data does not provide significantly useful insight into the real impact of benzodiazepine use on mortality within a population and therefore these studies were excluded from the presented results. From 9159 publications retrieved from the search, nine studies were included in the present review.

Figure 1: Search results



3. Results

3.1 Population-based registry studies

Three retrospective population-based registry studies, all from high income countries, were identified from the literature search. All three studies used differing types of estimates in their data analysis. Rogers *et al* examined a national database of calls received by US poison centres regarding poisoning and exposure cases and unveiled an extraordinarily high relative risk of death due to benzodiazepine poisoning versus other outcome in patients 60 or older when compared to under 60 (RR = 7.1, 95% CI = 3.2–15.5). The adjusted odds ratio of death for each 10-year increase in age was 1.7 (95% CI = 1.4–2.0)⁵⁵.

Using case-control responsibility analysis, Drummer *et al* examined the role of benzodiazepines in driver fatalities in on-road motor vehicle accidents. Benzodiazepines showed a positive association with driver-responsible fatalities (OR = 1.27, 95% CI = 0.5-3.3). However, because other drugs were detected post-mortem, the power of the study was reduced and the estimate was non-significant when presence of other drugs was controlled for ⁵⁶.

Lastly, Shah *et al* found some interesting age-standardised benzodiazepine associated mortality rates. Most deaths associated with benzodiazepine poisoning involved additional substances (71%), particularly opioids, but this study found that benzodiazepines caused 3.8% of all deaths caused by poisoning from a single drug. The age-standardized mortality rate (per million population) for males ranged from 7.1 in 1993 to 6.6 in 1998. For females, the rate ranged from 4.1 in 1993 to 2.4 in 1998⁵⁷.

Table 1 – Population-based registry studies of benzodiazepine-associated mortality

Reference	Location	Sample population	Sample size	Period of follow-up	Estimate																					
Rogers <i>et al</i> 2007	USA	All adult patients ≥ 20 yrs old on the Toxic Exposure Surveillance System (TESS) database	72,694	1995 – 2002	Acute poisoning mortality in 60 or older compared < 60 , unadjusted RR = 7.1 (95% CI = 3.2 to 15.5). Adjusted OR for each 10-year increase in age = 1.7 (95% CI = 1.4 to 2.0)																					
Drummer <i>et al</i> 2004	Vic, NSW and WA, Australia	Drivers killed in on-road motor vehicle crashes	3,389	1990 – 1999	Driver culpability OR = 1.27 (95%CI = 0.5–3.3)																					
Shah <i>et al</i> 2001	UK	Deaths from drug poisoning	15,720 deaths due to poisoning, of which 1667 were due to benzodiazepines (alone or in combination with another substance)	1993 – 1998	Age-standardized mortality rates (per million) <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th></th> <th>Males</th> <th>Females</th> </tr> </thead> <tbody> <tr> <td>1993</td> <td>7.1</td> <td>4.1</td> </tr> <tr> <td>1994</td> <td>7.3</td> <td>3.9</td> </tr> <tr> <td>1995</td> <td>6.7</td> <td>3.4</td> </tr> <tr> <td>1996</td> <td>6.8</td> <td>2.4</td> </tr> <tr> <td>1997</td> <td>7.0</td> <td>2.8</td> </tr> <tr> <td>1998</td> <td>6.6</td> <td>2.4</td> </tr> </tbody> </table>		Males	Females	1993	7.1	4.1	1994	7.3	3.9	1995	6.7	3.4	1996	6.8	2.4	1997	7.0	2.8	1998	6.6	2.4
	Males	Females																								
1993	7.1	4.1																								
1994	7.3	3.9																								
1995	6.7	3.4																								
1996	6.8	2.4																								
1997	7.0	2.8																								
1998	6.6	2.4																								

3.2 Cohort studies

Six prospective cohort studies meeting criteria were identified and are presented in Table 2. All studies were from high-income countries within Europe and North America.

Vinkers *et al* found relative risk (RR) of all-cause mortality was not increased in elderly users of benzodiazepines both before and after adjustment for confounding factors; RR were 0.77 (95% CI = 0.51–1.17), and 0.68 (95% CI = 0.44–1.04) respectively. However, an increase in fracture-related mortality was inferred, but not significant, with a hazard ratio of 2.71 (95% CI = 0.37–19.76). This finding is consistent with results from previous cross-sectional studies and highlights concerns about fracture-related mortality among the elderly⁷.

Another European study by Hausken *et al* supports an increased risk of mortality with daily use of benzodiazepines among those aged 40–42 (at baseline). Increased hazard ratios persisted for females after even the most comprehensive adjustment for confounding variables (RR = 1.5 [95% CI = 0.9–2.7] for men and 1.7 [95% CI = 1.1–2.6] for women). A dose-response relationship was observed with regular use being the highest risk for mortality⁴⁹.

A third cohort study by Hogan *et al* that examined an elderly population found no significant differences in mortality between users (54.8%) versus nonusers (53.2%) at baseline. However, no data analysis at follow-up was published to provide useful estimates⁵⁰. This study did not provide standardised estimates and thus did not meet the quality index criteria but was included for interest's sake given the limited number of studies available.

The paper by Gossop *et al* found a significant relationship between regular use of non-prescribed benzodiazepines and fatal overdose amongst 'drug misusers' (OR = 3.32, 95% CI = 1.58–6.97). It should be noted that typically more than one drug was detected at post-mortem. However, after adjustment for confounding effects of use of other substances the relationship held (OR = 2.86, 95% CI = 1.32–6.16)⁵¹.

In 1998, Kripke *et al*⁴ showed an association between prescription sleeping pill use and an increased risk of death within 6 years. The standardized mortality ratio (SMR) for men and women using at least 30 sleeping pills per month, adjusted for age, was 3.18 and 2.82, respectively ($p < 0.001$). After adjusting for a further 14 variables, the SMR for males and females was reduced to 1.17 (not significant) and 1.41 ($p < 0.001$) respectively. Hazard ratios (HR) associated with use of sleeping pills at least 30 times per month, adjusted for over 30 variables, were significant among older age groups. This built on findings from previous research^{52–54}, but used a more robust prospective cohort study-design which controlled for multiple variables. Among some age groups, the HRs associated with regular sleeping pill use was similar to the HRs of smoking 1–2 packs of cigarettes per day^{3,4}. Despite acknowledgement of bias and limitations, this study along with previous work propelled a debate regarding the real safety of benzodiazepines²⁵.

A study by Rumble and Morgan⁵⁴ assessing an elderly cohort from the general population did not find an increased risk of mortality among 'hypnotic' drug users. Although an initial association was found between increased mortality and the use of medication to aid sleep, once this category was broken down into 'hypnotic' medication (mainly benzodiazepines) and 'other' sleep medication, only the 'other' category persisted to be associated significantly with mortality. It should be noted that this study did not distinguish between those who used benzodiazepines infrequently and frequently.

Table 2 – Cohort studies examining benzodiazepine-associated mortality

Reference	Location	Sample population	Sample	Period of FU	Estimate (95% CI)
Vinkers <i>et al</i> 2003	Leiden, The Netherlands	All inhabitants of Leiden >85 years of age	599	1997 – 2002	All-cause mortality, adjusted RR = 0.68 (95% CI = 0.44-1.04). Fracture-related mortality, unadjusted RR = 2.71 (95% CI = 0.37-19.76)
Hausken <i>et al</i> 2007	Østfold and Aust-Agder, Norway	General population aged between 40 and 42 years of age	14,951	T1 = 1985 – 1989, follow-up = 18 years	All-cause mortality, adjusted hazard ratio = 1.5 (95% CI = 0.9–2.7) for men, and 1.7 (95% CI = 1.1–2.6) for women
Hogan <i>et al</i> 2003	Canada	General population >65 years of age	2,914	1990 – 1996	All-cause mortality of users (54.8%) versus nonusers (53.2%) at baseline (P=0.48) *
Gossop <i>et al</i> 2001	United Kingdom	Drug misusers in 54 treatment centres	1,075	1995 – 1999	Regular (weekly or more frequent) use of non-prescribed benzodiazepines associated with fatal overdose, adjusted OR = 2.86 (95% CI = 1.32 – 6.16)
Kripke <i>et al</i> 1998	United States of America	General population (not necessarily representative)	1,099,830	1982 – 1988	Standardised mortality ratios for use of sleeping pills 30+ times per month: Adjusted for age 3.18 for males and 2.82 for females (p<0.001). Adjusted for 15 variables 1.17 for males (ns) and 1.41 for females (p<0.001)
Rumble & Morgan 1992	England	General population, elderly (≥65 years of age)	1,042	1985-1990	Mortality of hypnotic users, Odds ratio, adjusted for sex, health risk and usual sleep duration: 1.02 (95% CI = 0.83-1.73)

4. Discussion

Six prospective cohort studies assessing the mortality risk of benzodiazepine use meeting the inclusion criteria were identified. The populations studied varied and included elderly populations, a middle-aged population, a general population sample and 'drug misusers'. All studies were from high-income countries within Europe and North America. None of the studies specifically examined *illicit* benzodiazepine use.

The results from the cohort studies are mixed and inconclusive; Vinkers *et al*, Rumble and Morgan and Hogan *et al* found no increased mortality among elderly users of benzodiazepines, whilst Hausken *et al* showed a positive association among females in a middle-aged population, and Kripke *et al* found significant relationships between mortality and benzodiazepine use, particularly among older groups. A dose-response relationship with frequency of use of benzodiazepines was also found in one study which supports the previous finding by Kripke *et al*^{4 49}. Rogers *et al* believes the large increased mortality in those over 60 years of age, compared to younger people, highlights the importance of increased effects and toxicity of benzodiazepines in the elderly, as described earlier⁵⁵.

In contrast to previous research^{58 59}, benzodiazepines did not show a strong positive association with driver culpability in fatal road accidents. However, this lack of an association may have been due to this study's lack of power to address the issue; benzodiazepines have been shown to increase crash risk in a number of epidemiological studies^{10 11 59-61}. While the rates in Shah *et al* are relatively low, it does highlight the fact that benzodiazepines do pose a risk and their safety should not be overestimated.

Increased mortality associated with benzodiazepine use has been clearly documented among "drug misusers". In a sample of injecting drug misusers, non-opiate drugs were involved in approximately half of fatal overdoses along with opiate drugs, and benzodiazepines made up the majority of this 'non-opiate' category²⁷. Other studies have found similar results²⁶.

4.1 Limitations

All studies to date, including Kripke *et al*, acknowledge serious limitations in their design and data. Perhaps the most significant and most difficult to overcome is the accurate certification of cause of death. In some of these papers no standardized system of identifying cause of death is obvious. This creates inherent problems with misclassification⁵¹. Some of the studies listed a standardized system as the method of diagnosing cause of death. But even an internationally standardized system such as ICD has limitations. It has not been established whether it is appropriate to consider all benzodiazepines as a class or whether there are differing risks associated with individual drugs. Small changes in coding of deaths over time create inconsistencies during observations of longitudinal trends⁴⁸. The skills of those who are assessing cause of death is a significant limitation and it appears reproducibility of diagnosis is often not proven.

Many of the sample populations used, particularly for retrospective analysis, are obtained through convenience sampling methods. These samples are usually not representative of the general population. Questionnaires and databases may be incomplete due to non-response, underreporting or incomplete follow-up^{49 55}. It is plausible that the increased rates of mortality associated with violent or reckless behaviour, such as that involved in driving, among benzodiazepine users may also be due to confounding by indication.

A further difficulty lies in the definitions of users and non-users of benzodiazepines. This review has not noted any significant consistency in these definitions. Vinkers *et al* description of a user was based on prescription duration of more than half of the study period⁷, whilst Hausken *et al* classified a user as someone who reported using any benzodiazepine in the last month⁴⁹. Stratification was done during analysis in some studies but was also extremely varied; for example, by number and/or type of benzodiazepine⁷, and by frequency of use⁵¹. It appears commonplace for the definition to be made at post-mortem through toxicology investigations. However a wide range of blood concentrations and a lack of clarity in what are 'toxic' blood levels of benzodiazepines make it difficult to assess the contribution of benzodiazepines in death. Furthermore, post-mortem drug concentrations are difficult to interpret and cannot be compared with single dose or steady-state concentrations in plasma.

In death among both benzodiazepine users and 'misusers', polydrug use has been identified again confusing the explicit role of benzodiazepines in the cause of death. The contributory effects of other drugs such as alcohol and opioids have been well documented⁵¹. This is merely one confounding factor creating an enormous complexity in the research.

The interplay of psychosocial, social, economic, biological and other variables complicates the relationship between benzodiazepine use and mortality^{49 51}. Benzodiazepines are psychoactive drugs and are often used in populations who suffer from comorbidity⁶². Exacerbation of sleep apnea, sedation, suppression of self-care functions, confusion, amnesia and disinhibition are suggested as possible psychopathological risks, which might help explain the increase in mortality⁴⁹. Users often also use other drugs or medication and may be more likely to be smokers or to be physically inactive⁶². Perhaps benzodiazepine use is merely a proxy for other risk factors associated with mortality. Confounding factors have been discussed at length by many studies and attempts to control for known or potential factors have been done on occasions. However, large variations in controlling for confounding factors was found between studies with some only adjusting for age and/or sex, whilst others for multiple variables^{7 49}.

All these factors make it extremely difficult to show a cause and effect relationship between benzodiazepine consumption and mortality and to date the findings from available literature cannot be considered anything more than exploratory. The true relationship between benzodiazepine use and increased mortality (and indeed other outcomes not discussed in this article) is still very unclear. Research has also yet to differentiate between different types of benzodiazepines. Currently we do not know

whether or not some benzodiazepines carry measurable mortality risk whilst others do not. If there is in fact an increased mortality risk, it is not known whether this risk is carried by certain 'at risk' populations who may have coexisting risk factors⁴.

Well-designed cohort and case-control studies can identify significant associations between various factors and outcomes, however, in concurrence with other authors, there is a need for long-term randomised, double-blind, parallel group, controlled trials of hypnotics. Only randomized controlled trials can control for the complexity of confounding factors to provide conclusive evidence of cause and effect. The necessity for a placebo control is of particular importance²⁵. A future research agenda should include a long-term controlled trial in users and non-users of benzodiazepines. It could be useful to include a third arm in the study for comparison with other hypnotic-sedative drugs. The sample population should be large and represent a large diversity of characteristics to assist in identification and controlling of confounders and subgroup analysis. Given the widespread use of benzodiazepines and the possible effects of confounding social and economic factors, it is also important to represent a diversity of countries. An international multi-centre trial including low- and middle-income countries, rather than only high-income countries, will be important, particularly as use and abuse of benzodiazepines in these countries can be expected to increase⁶³.

Although the primary objective of this paper was to examine the link between benzodiazepine use and mortality in the general population, the majority of the studies presented have examined the link in more 'at risk' populations such as injecting drug users, drivers, non-intentional fatal poisonings, suicide and the elderly. Such targeted research and demographic profiling of those at risk also remains to be critical so that information can be obtained and incorporated into targeted public health programs. Finally, published case-series literature will continue to provide further direction for future research.

4.2 Conclusions

The limited data suggesting elevated overall mortality among benzodiazepine users has not carefully examined whether users were taking medication as directed, or outside the directions of a medical professional. Guidelines for the use of benzodiazepines acknowledge adverse effects and inappropriate prescribing but there are many questions unanswered and recommendations are at times based on research of inadequate quality^{57 64 65}.

On the basis of existing research there is insufficient data to conduct a comparative risk assessment for benzodiazepine use. There are too few studies that report on specific causes of death and examine the risk of such causes of death relative to people who are not using benzodiazepines in an extra-medical manner.

The popularity of benzodiazepines among prescribers and patients should provide impetus for a thorough and conclusive investigation of benzodiazepine-associated mortality risk to prevent avoidable burden of disease and negative public health outcomes.

5. References

1. Taylor S, McCracken CFM, Wilson KCM, Copeland JRM. Extent and appropriateness of benzodiazepine use: results from an elderly urban community. *British Journal of Psychiatry* 1998;173:433-438.
2. Longo LP, Johnson B. Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives. *American Family Physician* 2000;61(7):2121-2128.
3. Kripke DF. Chronic hypnotic use: deadly risks, doubtful benefit. *Sleep Medicine Reviews* 2000;4(1):5-20.
4. Kripke DF, Klauber MR, Wingard DL, Fell RL, Assmus JD, Garfinkel L. Mortality hazard associated with prescription hypnotics. *Biological Psychiatry* 1998;43:687-693.
5. Windle A, Elliot E, Duszynski K, Moore V. Benzodiazepine prescribing in elderly Australian general practice patients. *Australian and New Zealand Journal of Public Health* 2007;31(4):379-381.
6. Rojas-Fernandez CH, Carver D, Tonks R. Population trends in the prevalence of benzodiazepine use in the older population of Nova Scotia: A cause for concern? *Canadian Journal of Clinical Pharmacology* 1999;6(3):149-156.
7. Vinkers DJ, Gussekloo J, van der Mast RC, Zitman FG, Westendorp RGJ. Benzodiazepine use and risk of mortality in individuals aged 85 years or older. *JAMA* 2003;290(22):2942-3.
8. *Australian Medicines Handbook*. Adelaide, 2005.
9. von Guten C, Weissman DE. Symptom control for ventilator withdrawal in the dying patient. *Journal of Palliative Medicine* 2003;6(5):774-775.
10. Hemmelgarn B, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. *JAMA* 1997;278(1):27-31.
11. Neutal CI. Risk of traffic accident injury after a prescription for a benzodiazepine. *Annals of Epidemiology* 1995;5(3):239-244.
12. Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. *Canadian Family Physician* 1998;44:799-808.
13. Drummer OH. Benzodiazepines - effects on human performance and behaviour. *Forensic Science Review* 2002;14(1):2-14.
14. Brookhuis KA, Volkerts ER, O'Hanlon JF. Repeated dose effects of lormetazepam and flurazepam upon driving performance. *European Journal of Clinical Pharmacology* 1990;39(1):83-87.
15. Laurell H, Tornros J. The carry-over effects of triazolam compared with nitrazepam and placebo in acute emergency driving situations and in monotonous simulated driving. *Acta Pharmacologica et Toxicologica* 1986;58(3):182-186.
16. O'Hanlon JF, Haak TW, Blaauw GJ, Riemersma JBJ. Diazepam impairs lateral position control in highway driving. *Science* 1982;217(4554):79-81.

17. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. *Journal of the American Medical Association* 1989;262(23):3303-3307.
18. Neutel CI, Hirdes JP, Maxwell CJ, Patten SB. New evidence on benzodiazepine use and falls: The time factor. *Age and Ageing* 1996;25(4):273-278.
19. Ray WA. Psychotropic drugs and injuries among the elderly: A review. *Journal of Clinical Psychopharmacology* 1992;12(6):386-396.
20. Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. *Drugs and Aging* 1998;12(1):43-53.
21. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: A systematic review and meta-analysis: I. Psychotropic drugs. *Journal of the American Geriatrics Society* 1999;47(1):30-39.
22. Passaro A, Volpato S, Romagnoni F, Manzoli N, Zuliani G, Fellin R. Benzodiazepines with different half-life and falling in a hospitalized population: The GIFA study. Gruppo Italiano di Farmacovigilanza nell'Anziano. *Journal of Clinical Epidemiology* 2000;53(12):1222-1229.
23. Dennis S, Charnet SJM, Harris RA. Hypnotics and sedatives. In: Brunton LL, editor. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. New York: McGraw-Hill, 2006.
24. Pandi-Perumal SR. *Clinical pharmacology of sleep. Overview of currently available benzodiazepine and nonbenzodiazepine hypnotics*. Boston: Basel, 2006.
25. Kramer M. Hypnotic medication in the treatment of chronic insomnia: non nocere! Doesn't anyone care? *Sleep Medicine Reviews* 2000;4(6):529-541.
26. Darke S, Ross J. Heroin-related deaths in South Western Sydney, Australia, 1992-96. *Drug and Alcohol Review* 1999;18:39-45.
27. Strang J, Griffiths P, Powis B, Fountain J, Williamson S, Gossop M. Which drugs cause overdose among opiate misusers? Study of personal and witnessed overdoses. *Drug and Alcohol Review* 1999;18:253-261.
28. Neale G, Smith AJ. Self-harm and suicide associated with benzodiazepine usage. *British Journal of General Practice* 2007;57:407-408.
29. Patten SB, Williamson JB, Love EJ. Self-reported depressive symptoms following treatment with corticosteroids and sedative-hypnotics. *International Journal of Psychiatry in Medicine* 1996;26(1):15-24.
30. Allgulander C, Nasman P. Regular hypnotic drug treatment in a sample of 32,679 Swedes: associations with somatic and mental health, inpatient psychiatric diagnoses and suicide, derived with automated record-linkage. *Psychosomatic Medicine* 1991;53(1):101-108.
31. Hall RC, Zisook S. Paradoxical reactions to benzodiazepines. *British Journal of Clinical Pharmacology* 1981;11(supplement 1):99S-104S.
32. Murray C, Lopez A. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. *Lancet* 1997;349:1436-1442.

33. Murray CJ, Lopez AD. *The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020*: Harvard University Press, 1996.
34. Drummer OH, Gerostamoulos J, Batziris H, Chu M, Caplehorn JRM, Robertson MD, et al. The incidence of drugs in drivers killed in Australian road traffic crashes. *Forensic Science International* 2003;134:154-162.
35. Buckley NA, McManus PR. Changes in fatalities due to overdose of anxiolytic and sedative drugs in the UK (1983-1999). *Drug Safety* 2004;27(2):135-41.
36. Carlsten A, Waern M, Holmgren P, Allebeck P. The role of benzodiazepines in elderly suicides. *Scandinavian Journal of Public Health* 2003;31(3):224-8.
37. Schwartz RA. How safe is long-term benzodiazepine pharmacotherapy? *Journal of Clinical Psychopharmacology* 2005;25(6):624-625.
38. Shields LBE, Hunsaker DM, Hunsaker JC, 3rd, Ward MK. Toxicologic findings in suicide: a 10-year retrospective review of Kentucky medical examiner cases. *American Journal of Forensic Medicine & Pathology* 2006;27(2):106-12.
39. Stenhouse G, Grieve JH. Drug-related deaths in Grampian, Scotland. *Scottish Medical Journal* 2003;48(4):111-3.
40. Bystrzycki A, Coleridge J. Drug- and poison-related deaths in Victoria during 1997. *Emergency Medicine* 2000;12:303-309.
41. Carmen del Rio M, Gomez J, Sancho M, Alvarez FJ. Alcohol, illicit drugs and medicinal drugs in fatally injured drivers in Spain between 1991 and 2000. *Forensic Science International* 2002;8(1-2):63-70.
42. Druid H, Holmgren P, Ahlner J. Flunitrazepam: An evaluation of use, abuse and toxicity. *Forensic Science International* 2001;122:136-141.
43. Jonsson A, Holmgren P, Ahlner J. Fatal intoxications in a Swedish forensic autopsy material during 1992-2002. *Forensic Science International* 2004;143(1):53-9.
44. Schwilke EW, Sampaio dos Santos MI, Logan BK. Changing patterns of drug and alcohol use in fatally injured drivers in Washington State. *Journal of Forensic Sciences* 2006;51(5):1191-8.
45. Seymour A, Oliver JS. A study of alcohol and drugs in impaired and fatally injured drivers in the west of Scotland. *Journal of Traffic Medicine* 2000;28(3-4):32-37.
46. Shah R, Uren Z, Baker A, Majeed A. Trends in suicide from drug overdose in the elderly in England and Wales, 1993-1999. *International Journal of Geriatric Psychiatry* 2002;17(5):416-21.
47. Wolf BC, Lavezzi WA, Sullivan LM, Middleberg RA, Flannagan LM. Alprazolam-related deaths in Palm Beach County. *American Journal of Forensic Medicine & Pathology* 2005;26(1):24-7.
48. Wysowski DK. Surveillance of prescription drug-related mortality using death certificate data. *Drug Safety* 2007;30(6):533-540.

49. Hausken AM, Skurtveit S, Tverdal A. Use of anxiolytic or hypnotic drugs and total mortality in a general middle-aged population. *Pharmacoepidemiology & Drug Safety* 2007;16(8):913-8.
50. Hogan DB, Maxwell CJ, Fung TS, Ebly EM. Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian Study of Health and Aging. *Canadian Journal of Clinical Pharmacology* 2003;10(2):72-77.
51. Gossop M, Stewart D, Treacy S, Marsden J. A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. *Addiction* 2002;97(1):39-47.
52. Allgulander C. History and current status of sedative-hypnotic drug use and abuse. *Acta Psychiatrica Scandinavica* 1986;73(5):465-478.
53. Kripke DF, Simons RN, Garfinkel L, Hammond EC. Short and long sleep and sleeping pills. Is increased mortality associated? *Archives of General Psychiatry* 1979;36(1):103-116.
54. Rumble R, Morgan K. Hypnotics, sleep, and mortality in elderly people. *Journal of the American Geriatrics Society* 1992;40(8):787-791.
55. Rogers JJ, Heard K. Does age matter? Comparing case fatality rates for selected poisonings reported to U.S. poison centers. *Clinical Toxicology: The Official Journal of the American Academy of Clinical Toxicology & European Association of Poisons Centres & Clinical Toxicologists* 2007;45(6):705-8.
56. Drummer OH, Gerostamoulos J, Batziris H, Chu M, Caplehorn J, Robertson MD, et al. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. *Accident Analysis & Prevention* 2004;36(2):239-48.
57. Shah R, Uren Z, Baker A, Majeed A. Trends in deaths from drug overdose and poisoning in England and Wales 1993-1998. *Journal of Public Health Medicine* 2001;23(3):242-6.
58. Longo MC, Hunter CE, Lokan RJ, White JM, White MA. The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability: part ii: the relationship between drug prevalence and drug concentration, and driver culpability. *Accident Analysis & Prevention* 2000;32(5):623-632.
59. Longo MC, Lokan RJ, White JM. The relationship between blood benzodiazepine concentration and vehicle crash culpability. *Journal of Traffic Medicine* 2001;29(1-2):36-43.
60. Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG, et al. Association of road-traffic accidents with benzodiazepine use. *Lancet* 1998;352(9137):1331-1336.
61. Skegg DCG, Richards SM, Doll R. Minor tranquillisers and road accidents. *British Medical Journal* 1979;1:917-919.
62. Laurier C, Dumas J, Grégoire J-P. Factors Related to Benzodiazepine Use in Quebec - A Secondary Analysis of Survey Data *Journal of Pharmacoepidemiology* 1992;2(4):73-86.

63. Eddleston M. Patterns and problems of deliberate self-poisoning in the developing world. *Qjm* 2000;93(11):715-31.
64. Blanchard MR, Waterreus A, Mann AH. The nature of depression among older people in inner London, and the contact with primary care. *British Journal of Psychiatry* 1994;164(3):396-402.
65. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. *Canadian Medical Association Journal* 1997;156(3):385-391.

Annex 1: Search strategy

Databases included were Embase, PsycInfo, and Medline.

Search terms:

Mortality

Mortal\$ or fatal\$ or death\$

**exp DEATH/ or exp "CAUSE OF DEATH"/ or exp SUDDEN DEATH/ or exp Mortality/
or exp Hospitalization/ or exp Fatal Outcome/**

AND

Benzodiazepines

Benzodiazepine\$ OR benzo OR Benzos OR alprazolam OR anthramycin OR benzodiazepinones OR brotizolam OR bromazepam OR camazepam OR chlordiazepoxide OR cinolazepam OR clonazepam OR clorazepate OR clorazepate dipotassium OR clotiazepam OR cloxazolam OR delorazepam OR devazepide OR diazepam OR etizolam OR estazolam OR fludiazepam OR flumazenil OR flunitrazepam OR flurazepam OR halazepam OR haloxazolam OR ketazolam OR loprozepam OR lorazepam OR lormetazepam OR medazepam OR midazolam OR nimetazepam OR nitrazepam OR nordazepam OR oxazolam OR oxazepam OR phenazepam OR pinazepam OR pirenzepine OR prazepam OR quazepam OR temazepam OR tetrazepam OR tofisopam OR triazolam OR Xanax OR Lexomil OR Valium OR Ativan OR Klonopin OR Restoril OR Serax OR Rohypnol OR Halcion OR Librium OR Dalmane OR ProSom OR Mogadon

**exp "hypnotics and sedatives"/ or exp anti-anxiety agents/ or exp benzodiazepines/ or
exp benzodiazepinones/ or exp alprazolam/ or exp bromazepam/ or exp
chlordiazepoxide/ or exp clonazepam/ or exp clorazepate dipotassium/ or exp
devazepide/ or exp diazepam/ or exp estazolam/ or exp flumazenil/ or exp
flunitrazepam/ or exp flurazepam/ or exp lorazepam/ or exp medazepam/ or exp
midazolam/ or exp nitrazepam/ or exp nordazepam/ or exp oxazepam/ or exp
pirenzepine/ or exp prazepam/ or exp temazepam/ or exp triazolam/**

Annex 2: Quality index

Case ascertainment

- Community survey/Multiple institutions=2
- Inpatient/In & out patients/case registers=1
- Not specified =0

Methods of diagnostic assignment

- Interview= 3
- Systematic casenote review=2
- Chart Diagnosis/casenote=1
- Not specified=0

*self-reported use of drug = 3

*blood and/or urine toxicological screen = 2

Diagnosis

- Any diagnostic system reported eg., DSM, ICD, RDC =1
- Own system/symptoms described/No system/Not specified=0

*dependence = 1 (include comment, eg. In treatment centre)

S_Rate/estimate/SMR presented

- Y/N

*included comment indicating what type of estimate (eg. relative risk)

Are the numerator AND denominator presented

- Y/N

Are the numerator and denominator based on identical epochs?

- Y/N

Are the numerator and denominator based on identical catchment areas?

- Y/N

Completeness of case ascertainment

- 2=excellent
- 1=average

- 0=poor
- *if exclusions made/low response rate = 1

Representativeness of the catchment area with respect to the nation

- 2=well representative
- 1=small area/not representative
- 0=convenient sampling/other

Are the data adjusted for age and/or sex?

- Y/N

S_How STD

- text about what variables have been controlled

Is there any mention of reliability of raters etc

- Y/N

Sample Bias

- Y/N

Quality of methods/reporting - eg. *translation of tools, interviewer's quality, quality control monitoring etc*

Duration of follow up

- >10years=2
- between 2 & 9=1
- <2=0

Is the attrition rate presented?

- Y/N

Note: *additional merit for any "Text" =1 to be considered by the study reviewer